Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Patronus AI unveiled “Generative Simulators,” adaptive “practice worlds” that replace static benchmarks with dynamic ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

1. Risk: AI Monoculture (Shared Blind Spots). This is the most critical and overlooked systemic vulnerability. Building your ...

Calling for a revival of the concept of a co-operative commonwealth as a “solidarity stack” to reshape AI, he added: ...

Getting good at LeetCode Java can feel like a puzzle sometimes, right? You see all these problems, and you’re not sure where ...

Getting good at LeetCode Java isn’t just about solving problems; it’s about having a good plan. You need to know where to ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...